Release date: 2009-08-14
In a groundbreaking move, Japanese media reported that starting in late August, the University of Tokyo Affiliated Hospital will launch a clinical trial using transgenic viruses to treat malignant brain tumors. This marks the first such study in Japan, offering hope for a new approach in cancer therapy.
The focus of the research is on glioblastoma, one of the most aggressive forms of brain cancer. These tumors grow rapidly and often lead to a short survival time, even after surgery, radiation, and chemotherapy. On average, patients live only 12 to 14 months, and if the tumor recurs, life expectancy drops to just 5 to 9 months.
To tackle this deadly disease, scientists have modified a herpes virus, making it more targeted toward cancer cells while minimizing harm to healthy tissue. By enhancing its ability to attack malignant cells directly, researchers aim to improve treatment outcomes.
The trial will involve patients who have experienced a recurrence of glioblastoma. They will receive two injections of the genetically modified herpes virus into the tumor site over a period of two weeks. Researchers will closely monitor changes in tumor size and any neurological symptoms. The entire trial is expected to last for two years.
Experts believe that this type of gene-modified viral therapy could become one of the most effective and safest treatments for brain cancer in the future. In 2005, a study published in *Cancer Research* showed that transgenic viruses successfully extended the lifespan of mice with human brain tumors without damaging healthy cells. As research continues, this innovative method may revolutionize how we treat some of the most challenging cancers. Meditech Medical Network
Fish Fillet
Fish Fillet,Crusted Cod,Hake Fillets For Sale,Salmon Fish Fillet
ZHEJIANG EVERNEW SEAFOOD CO.,LTD , https://www.evernewseafood.com